SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-23-017579
Filing Date
2023-05-11
Accepted
2023-05-11 16:21:00
Documents
14
Period of Report
2023-05-11
Items
Item 2.02: Results of Operations and Financial Condition

Document Format Files

Seq Description Document Type Size
1 8-K mnlo-20230511.htm   iXBRL 8-K 35060
2 EX-99.1 vyne-20230511q1x2023exx991.htm EX-99.1 148924
6 image.jpg GRAPHIC 16124
  Complete submission text file 0001628280-23-017579.txt   362875

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mnlo-20230511.xsd EX-101.SCH 2026
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mnlo-20230511_lab.xml EX-101.LAB 25136
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mnlo-20230511_pre.xml EX-101.PRE 13154
8 EXTRACTED XBRL INSTANCE DOCUMENT mnlo-20230511_htm.xml XML 11254
Mailing Address 685 ROUTE 202/206 N., SUITE 301 BRIDGEWATER NJ 08807
Business Address 685 ROUTE 202/206 N., SUITE 301 BRIDGEWATER NJ 08807 800-775-7936
VYNE Therapeutics Inc. (Filer) CIK: 0001566044 (see all company filings)

IRS No.: 453757789 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38356 | Film No.: 23911374
SIC: 2834 Pharmaceutical Preparations